NM 004
Alternative Names: 5-ASA+4-APAA; Apaza™; INN-108; NAA-004; NM-004Latest Information Update: 23 Mar 2023
At a glance
- Originator Biocon
- Developer 9 Meters Biopharma
- Class Anti-inflammatories; Nitrogen compounds; Phenylacetates; Radioprotectives; Salicylic acids; Small molecules
- Mechanism of Action Immunomodulators; Interleukin 2 stimulants; Lipoxygenase-cyclooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Inflammatory bowel diseases; Radiation injuries; Ulcerative colitis
Most Recent Events
- 23 Mar 2023 Discontinued - Phase-I for Ulcerative colitis (In adolescents, In children, In the elderly, In infants, In neonates, In adults) in USA (PO)
- 22 Mar 2023 Discontinued - Phase-I for Ulcerative colitis (In adults) in USA (PO)
- 19 Jul 2022 Discontinued - Phase-I for Inflammatory bowel diseases in USA (PO) (9 Meters Biopharma pipeline, July 2022)